IU
MCID: INT064
MIFTS: 55

Intermediate Uveitis (IU)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Intermediate Uveitis

MalaCards integrated aliases for Intermediate Uveitis:

Name: Intermediate Uveitis 12 58 15 17
Uveitis, Intermediate 43 71
Peripheral Uveoretinitis 12
Uveitis Intermediate 54
Chronic Cyclitis 12
Iu 58

Characteristics:

Orphanet epidemiological data:

58
intermediate uveitis
Inheritance: Not applicable; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12732
MeSH 43 D015867
NCIt 49 C35110
SNOMED-CT 67 314429009
ICD10 via Orphanet 33 H30.2
UMLS via Orphanet 72 C0042166
Orphanet 58 ORPHA279914
UMLS 71 C0042166

Summaries for Intermediate Uveitis

MalaCards based summary : Intermediate Uveitis, also known as uveitis, intermediate, is related to pars planitis and macular retinal edema. An important gene associated with Intermediate Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mycophenolic acid and Fluocinolone Acetonide have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cataract and glaucoma

Wikipedia : 74 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary sites... more...

Related Diseases for Intermediate Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Infectious Posterior Uveitis Systemic Diseases with Anterior Uveitis
Systemic Diseases with Posterior Uveitis

Diseases related to Intermediate Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 709)
# Related Disease Score Top Affiliating Genes
1 pars planitis 32.1 MRAP IL2 HLA-DRB1 HLA-B CCR6
2 macular retinal edema 30.6 TNF MRAP IL6
3 vasculitis 30.5 TNF IL6 IL10 HLA-B
4 retinal detachment 30.5 TNF IL6 IL10 IFNG
5 drug reaction with eosinophilia and systemic symptoms 30.3 TNF HLA-B
6 poliomyelitis 30.3 TNF IL10 IFNG
7 lyme disease 30.3 TNF IL6 HLA-DRB1
8 bacterial vaginosis 30.3 TNF IL6 IL10
9 multifocal choroiditis 30.3 TNF IL10
10 diphtheria 30.0 TNF IL2RA IL2 IFNG
11 neuritis 30.0 TNF IL6 IL10 IFNG CCR5
12 ocular tuberculosis 30.0 MRAP IFNG
13 retinal vasculitis 30.0 TNF MRAP CCR6
14 food allergy 30.0 TNF IL10 IFNG
15 hepatitis c 29.9 TNF IL10 IFNG CCR5
16 allergic bronchopulmonary aspergillosis 29.9 IL10 IFNG HLA-DRB1
17 bone resorption disease 29.9 TNF IL6 CCR6
18 thyroiditis 29.8 TNF IL6 IL2 IL10
19 endophthalmitis 29.8 TNF MRAP IL6
20 pertussis 29.8 TNF IL6 IL10
21 familial mediterranean fever 29.8 TNF IL6 IL10
22 pulpitis 29.8 TNF IL6 CCR6
23 pharyngitis 29.8 TNF IL6 HLA-DRB1
24 yellow fever 29.7 IL6 CCR6 CCR5
25 eosinophilic pneumonia 29.7 IL6 CD69 CCR4
26 bronchitis 29.7 TNF IL6 IL10
27 cervicitis 29.7 TNF IL6 IL2RA IL2
28 lymphoma, hodgkin, classic 29.7 IL2RA IL2 CCR6 CCR4
29 rhinitis 29.7 TNF IL6 IL10 IFNG
30 inflammatory bowel disease 1 29.7 TNF IL6 CCR6
31 interstitial lung disease 29.7 TNF IL6 IL10 IFNG
32 iridocyclitis 29.6 TNF MRAP IL6 IL10 HLA-B
33 toxoplasmosis 29.6 TNF IL6 IL10 IFNG CCR5
34 fuchs' heterochromic uveitis 29.5 MRAP IL6 IFNG
35 autoimmune hepatitis 29.5 TNF IL6 IL10 HLA-DRB1
36 diarrhea 29.4 TNF IL6 IL2 IL10 IFNG
37 allergic asthma 29.4 IL2RA IL10 IFNG CD69
38 dysentery 29.4 TNF IL6 IL10 CCR6
39 common cold 29.4 TNF IL6 IL10 CCR6
40 acute cystitis 29.4 TNF IL6 IL10 CCR6
41 aspergillosis 29.4 TNF IL6 IL10 IFNG CCR6
42 acute disseminated encephalomyelitis 29.3 IL10 HLA-DRB1 HLA-B CCR6
43 toxic shock syndrome 29.3 TNF IL6 IL2 IL10 IFNG
44 pneumonia 29.3 TNF IL6 IL2 IL10 IFNG
45 optic neuritis 29.2 TNF IL6 IL2RA IL10 HLA-DRB1 CXCR3
46 tetanus 29.2 TNF IL6 IL2RA IL2 IL10 IFNG
47 stomatitis 29.2 TNF IL6 IL2 IL10 IFNG
48 tonsillitis 29.2 TNF IL6 IL2 IL10 IFNG
49 brucellosis 29.2 TNF IL6 IL2 IL10 IFNG
50 vaginitis 29.2 TNF IL6 IL10 CCR6 CCR5

Graphical network of the top 20 diseases related to Intermediate Uveitis:



Diseases related to Intermediate Uveitis

Symptoms & Phenotypes for Intermediate Uveitis

Human phenotypes related to Intermediate Uveitis:

58 31 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 cataract 58 31 occasional (7.5%) Occasional (29-5%) HP:0000518
2 glaucoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0000501
3 reduced visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0007663
4 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
5 optic neuritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100653
6 anterior uveitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012122
7 vitreous floaters 58 31 occasional (7.5%) Occasional (29-5%) HP:0100832
8 epiretinal membrane 58 31 occasional (7.5%) Occasional (29-5%) HP:0100014
9 cystoid macular edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0011505
10 band keratopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000585
11 posterior synechiae of the anterior chamber 58 31 occasional (7.5%) Occasional (29-5%) HP:0011484
12 vitreous haze 58 31 occasional (7.5%) Occasional (29-5%) HP:0030652
13 vitreous snowballs 58 31 occasional (7.5%) Occasional (29-5%) HP:0030661
14 psoriasiform dermatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0003765
15 tubulointerstitial nephritis 58 31 very rare (1%) Very rare (<4-1%) HP:0001970
16 macular scar 58 31 very rare (1%) Very rare (<4-1%) HP:0200056
17 chronic infection 58 31 very rare (1%) Very rare (<4-1%) HP:0031035
18 macular edema 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Intermediate Uveitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.15 CCR4 CCR5 CCR6 CD69 CXCR3 IFNG
2 cardiovascular system MP:0005385 10.13 CCR5 CCR6 CXCR3 IFNG IL10 IL2
3 immune system MP:0005387 10.1 CCR4 CCR5 CCR6 CD69 CXCR3 IFNG
4 digestive/alimentary MP:0005381 9.95 CCR5 IFNG IL10 IL2 IL2RA IL6
5 liver/biliary system MP:0005370 9.86 CCR5 IFNG IL10 IL2 IL6 MRAP
6 neoplasm MP:0002006 9.7 CCR5 CXCR3 IFNG IL10 IL2 IL6
7 respiratory system MP:0005388 9.61 CCR4 CXCR3 IFNG IL10 IL2 IL2RA
8 vision/eye MP:0005391 9.23 CCR5 IFNG IL10 IL2 IL2RA IL6

Drugs & Therapeutics for Intermediate Uveitis

Drugs for Intermediate Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Chlorambucil Approved Phase 4 305-03-3 2708
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
8
Azathioprine Approved Phase 4 446-86-6 2265
9 Anti-Infective Agents Phase 4
10 Antiemetics Phase 4
11 BB 1101 Phase 4
12 Antitubercular Agents Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antibiotics, Antitubercular Phase 4
15 Antifungal Agents Phase 4
16 Alkylating Agents Phase 4
17 Cyclosporins Phase 4
18 Calcineurin Inhibitors Phase 4
19 Hormones Phase 4
20 Hormone Antagonists Phase 4
21 Adrenocorticotropic Hormone Phase 4
22 Melanocyte-Stimulating Hormones Phase 4
23 beta-Endorphin Phase 4
24
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
27
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
28
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
29
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
30 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
31
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
32
Adalimumab Approved Phase 3 331731-18-1 16219006
33
Sodium citrate Approved, Investigational Phase 3 68-04-2
34
Infliximab Approved Phase 3 170277-31-3
35
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
36
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
37 Triamcinolone diacetate Phase 3
38 triamcinolone acetonide Phase 3
39 Triamcinolone hexacetonide Phase 3
40 Interferon-beta Phase 3
41 interferons Phase 3
42 Antiviral Agents Phase 3
43
protease inhibitors Phase 2, Phase 3
44 HIV Protease Inhibitors Phase 2, Phase 3
45 Methylprednisolone Acetate Phase 3
46 Citrate Phase 3
47 Chelating Agents Phase 3
48 Ophthalmic Solutions Phase 3
49 Anti-Infective Agents, Local Phase 3
50 Neuroprotective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
2 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
3 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
4 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) Suspended NCT03656692 Phase 4 Acthar Gel
5 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Unknown status NCT02746991 Phase 3 Sham Injection;FAI Insert
6 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
7 A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM) Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
8 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
9 Myfortic (Enteric-coated Mycophenolate Sodium) for the Treatment of Non-infectious Intermediate Uveitis - a Prospective, Controlled, Randomized Multicenter Trial Completed NCT01092533 Phase 3 Myfortic;Decortin
10 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
11 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
12 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
13 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
14 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
15 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
17 A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis Completed NCT01505088 Phase 3 40 mg/mL Dexamethasone phosphate ophthalmic solution;Prednisolone Acetate (1%) Eyedrops;100 mM sodium citrate buffer solution;Placebo Eyedrops
18 A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study Terminated NCT02375685 Phase 3
19 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
20 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
21 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
22 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01103024 Phase 3
23 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
24 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
25 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
26 Infliximab for Diabetic Macular Edema Refractory to Laser Photocoagulation: a Randomized, Double-Masked, Placebo-Controlled, Cross-Over, 32 Weeks Study Terminated NCT00505947 Phase 3 infliximab;placebo
27 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
28 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
29 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
30 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
31 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
32 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
33 An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
34 The Treatment of Macular Edema Secondary to Uveitis Using Topical Interferon Gamma Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
35 Evaluation of Subcutaneous Daclizumab Treatments in Patients With Non-Infectious Sight-Threatening Uveitis: A Multicenter, Open-Label, Phase II Study Completed NCT00043667 Phase 2 Daclizumab
36 An Open-label, Multi-center, Randomized, Phase II Study of the Safety, and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis Recruiting NCT02931175 Phase 2 ACTH gel
37 Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
38 A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis Recruiting NCT02911116 Phase 2 Ustekinumab;Ustekinumab
39 A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU) Recruiting NCT03847272 Phase 2 prednisone and ustekinumab treatment
40 A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis Terminated NCT02125266 Phase 1, Phase 2 V404
41 Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate Terminated NCT01314417 Phase 1, Phase 2 Methotrexate
42 A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis Withdrawn NCT01905124 Phase 2 CF101;Placebo
43 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
44 A Pilot Study to Investigate Ustekinumab (StelaraTM) for the Treatment of Active Sight-Threatening Uveitis Withdrawn NCT01647152 Phase 1, Phase 2 Ustekinumab
45 A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
46 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b
47 Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis Unknown status NCT02879084
48 Influence of Macular Edema on Quality of Life in Patients With Non-infectious Intermediate Uveitis Completed NCT01314469
49 Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis Completed NCT02952001 4mg CLS-TA Suprachoriodal Injection
50 A Pilot Study to Demonstrate the Presence of Vascular Endothelial Growth Factor (VEGF) in Uveitic Cystoid Macular Edema Completed NCT00001738

Search NIH Clinical Center for Intermediate Uveitis

Cochrane evidence based reviews: uveitis, intermediate

Genetic Tests for Intermediate Uveitis

Anatomical Context for Intermediate Uveitis

MalaCards organs/tissues related to Intermediate Uveitis:

40
Eye, Retina, Endothelial, T Cells, Testes, B Cells, Myeloid

Publications for Intermediate Uveitis

Articles related to Intermediate Uveitis:

(show top 50) (show all 701)
# Title Authors PMID Year
1
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. 54 61
15878055 2005
2
Serum cytokine receptor levels in noninfectious uveitis. 54 61
15746567 2005
3
Systemic CD4(+) T cell phenotype and activation status in intermediate uveitis. 54 61
14977779 2004
4
Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. 61
32408154 2020
5
Clinical utility of aqueous humor polymerase chain reaction and serologic testing for suspected infectious uveitis: a single-center retrospective study in South Korea. 61
32560636 2020
6
Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target. 61
32274442 2020
7
Response: comment on 'Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis': Letter to the Editor. 61
31773855 2020
8
Comment on 'Swept-source optical coherence tomography angiography reveals vascular changes in intermediate uveitis'. 61
31736253 2020
9
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2020
10
Pediatric Uveitis in a Referral Center in North Part of Turkey. 61
32463707 2020
11
Development of Vitreoretinal Lymphoma in a Patient with Sarcoid Uveitis. 61
31268740 2020
12
[Intermediate Uveitis in Adults and Children - Update]. 61
32274779 2020
13
Pattern of Intermediate Uveitis in an Egyptian Cohort. 61
31642742 2020
14
Pattern and Outcome of Uveitis in a Tertiary Military Hospital in Thailand. 61
31009267 2020
15
The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings. 61
32250731 2020
16
Ocular syphilis in Pacific peoples-are we making misdiagnoses secondary to yaws? 61
32325468 2020
17
[Treatment of noninfectious intermediate uveitis, posterior uveitis, or panuveitis]. 61
31818505 2020
18
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program. 61
32564920 2020
19
Bilateral Anterior and Intermediate Uveitis Associated With Omeprazole. 61
31744307 2020
20
Reply To: "Abd El Latif Et Al. Pattern of Intermediate Uveitis in an Egyptian Cohort". 61
32125199 2020
21
Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. 61
32199631 2020
22
Pattern of uveitis in a tertiary eye care center of central India: Results of a prospective patient database over a period of two years. 61
32057007 2020
23
Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. 61
31607412 2020
24
Patterns of Uveitis in Egypt. 61
32068471 2020
25
The Detection of Occult Retinal Vasculitis on Fluorescein Angiography in Pediatric Uveitis. 61
31708487 2020
26
Use of Anti-Tumour Necrosis Factor-Alpha Agents in the Management of HLA-B-27-Associated Uveitis: The First Case Series from India. 61
32058826 2020
27
Intermediate Uveitis Associated with Tattooing of Eyebrows as a Manifestation of Systemic Sarcoidosis: Report of Two Cases. 61
31944169 2020
28
INTERMEDIATE UVEITIS WITH RETINAL DETACHMENT IN A PATIENT WITH POMPE DISEASE. 61
31996560 2020
29
Changing pattern of clinical manifestations of Behçet's disease in Tunisia: comparison between two decades. 61
32476681 2020
30
Ocular Autoimmune Systemic Inflammatory Infectious Study (OASIS) - Report 2: Pattern of Uveitis Investigations in Singapore. 61
30335550 2020
31
Evaluation of factors for predicting risk of uveitis recurrence in Behcet's disease patients. 61
32401930 2020
32
Objective quantification of vitreous haze on optical coherence tomography scans: no evidence for relationship between uveitis and inflammation in multiple sclerosis. 61
31342606 2020
33
Cytopathology and Polymerase Chain Reaction of Vitreous Fluid in Tubercular Intermediate Uveitis. 61
31906764 2020
34
Risk factors for ocular complications in adult patients with uveitis. 61
31902244 2020
35
Uveitis and Multiple Sclerosis: Potential Common Causal Mutations. 61
31161422 2019
36
[Systemic biological treatment in ophthalmology]. 61
31657252 2019
37
Bartonella henselae- and quintana-associated uveitis: a case series and approach of a potentially severe disease with a broad spectrum of ocular manifestations. 61
30852734 2019
38
Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis. 61
31302765 2019
39
Artisan-style iris-claw intraocular lens implantation in patients with uveitis. 61
31585851 2019
40
Tubercular intermediate uveitis: The importance of meticulous multidisciplinary assessments. 61
31638053 2019
41
The Clinical Characteristics of Pediatric Non-Infectious Uveitis in Two Tertiary Referral Centers in Turkey. 61
31687865 2019
42
Intermediate Uveitis as the Initial and Only Presentation of Syphilis 61
31650814 2019
43
VASOPROLIFERATIVE TUMORS IN INTERMEDIATE UVEITIS. 61
31584561 2019
44
[Epidemiologic and etiologic patterns of uveitis in a University Hospital]. 61
31164299 2019
45
Sarcoidosis presenting with intermediate uveitis and subcutaneous nodules. 61
31501183 2019
46
Uveitis: Autoimmunity… and beyond. 61
31323361 2019
47
Use of Immunomodulatory Drugs at a Uveitis Clinic. 61
29132749 2019
48
Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial. 61
31503307 2019
49
Etiologic Spectrum and Follow-Up Results of Noninfectious Uveitis in Children: A Single Referral Center Experience. 61
31598595 2019
50
Evaluation of vascular changes in intermediate uveitis and retinal vasculitis using swept-source wide-field optical coherence tomography angiography. 61
30538102 2019

Variations for Intermediate Uveitis

Expression for Intermediate Uveitis

Search GEO for disease gene expression data for Intermediate Uveitis.

Pathways for Intermediate Uveitis

Pathways related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF IL6 IL2RA IL2 IL10 IFNG
2
Show member pathways
13.82 TNF TGFBR3 IL6 IL2RA IL2 IL10
3
Show member pathways
13.66 TNF IL6 IL2RA IL2 IL10 IFNG
4
Show member pathways
13.5 TNF TGFBR3 IL6 IL2RA IL2 IL10
5
Show member pathways
13.38 TNF IL6 IL2RA IL2 IL10 CXCR3
6
Show member pathways
13.33 TNF IL6 IL2RA IL2 IL10 IFNG
7
Show member pathways
13.17 TNF TGFBR3 IL6 IL2RA IL2 IL10
8
Show member pathways
12.95 TNF IL6 IL2RA IL2 HLA-B
9
Show member pathways
12.91 TNF IL6 HLA-B CCR5 CCR4
10
Show member pathways
12.81 TNF IL6 IL2RA IL2 IFNG HLA-DRB1
11 12.79 TNF IL6 IFNG HLA-DRB1 HLA-B
12
Show member pathways
12.78 TNF IL6 IL2RA IL2 IL10 IFNG
13
Show member pathways
12.68 TNF IL2RA IL2 IL10 IFNG HLA-DRB1
14
Show member pathways
12.64 TNF IL6 IL2 IL10 IFNG CCR5
15
Show member pathways
12.62 TNF IL6 IL2 IL10 IFNG
16 12.59 TNF IL2RA IL2 IL10 IFNG
17
Show member pathways
12.54 TNF IL6 IL2RA IL2 IL10 IFNG
18
Show member pathways
12.49 TNF IL2 IFNG HLA-B
19
Show member pathways
12.49 IL6 IL2RA IL2 IL10 IFNG CCR5
20
Show member pathways
12.34 TNF IL6 IL2 IFNG
21
Show member pathways
12.32 TNF IL10 IFNG HLA-DRB1 CCR5
22 12.31 TNF IL6 IL2RA IL2 HLA-DRB1 HLA-B
23 12.29 TNF IL6 IL10 IFNG HLA-DRB1
24
Show member pathways
12.23 TNF IL6 IL2 IL10
25
Show member pathways
12.13 TNF TGFBR3 IL6 IL2RA IL2 IL10
26 12.06 TNF IL6 IL2 IL10
27 12.05 TNF IL6 IL2 IFNG
28
Show member pathways
11.99 IL2RA IL2 IFNG HLA-DRB1 CCR5
29 11.98 TNF IL6 IL10 IFNG
30 11.96 TNF IL6 IL10
31 11.96 TNF IL6 IL2RA HLA-DRB1
32
Show member pathways
11.95 TNF IL6 IL2 IL10 IFNG
33 11.93 TNF IL6 IFNG HLA-DRB1
34 11.87 TNF IL6 IL2RA IL2 IL10 IFNG
35
Show member pathways
11.85 TGFBR3 IL6 IFNG
36
Show member pathways
11.84 TNF IL2RA IL2 IFNG
37 11.8 IL6 IL2 IFNG
38 11.77 TNF IL6 IL10
39
Show member pathways
11.74 TNF IL6 IL2 IFNG
40 11.74 TNF IL6 IL2 IL10 IFNG
41
Show member pathways
11.71 TNF IL2RA IL2 IFNG
42 11.64 TNF TGFBR3 IFNG
43 11.61 TNF IL6 IL2 IFNG
44
Show member pathways
11.61 TNF IL6 IL2RA IL2 IL10 CXCR3
45 11.6 TNF IL6 IL10 IFNG
46 11.6 TNF IL2RA IL2 IL10 IFNG CXCR3
47 11.58 TNF IL6 IL10 CCR5
48 11.56 TNF IL2 IFNG
49 11.54 IL2RA IL2 IL10 IFNG
50 11.52 TNF IL6 IFNG

GO Terms for Intermediate Uveitis

Cellular components related to Intermediate Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.06 TNF TGFBR3 MRAP IL2RA HLA-DRB1 HLA-B
2 extracellular space GO:0005615 9.91 TNF TGFBR3 IL6 IL2 IL10 IFNG
3 integral component of plasma membrane GO:0005887 9.81 TNF TGFBR3 HLA-DRB1 HLA-B CXCR3 CD69
4 cell GO:0005623 9.73 IL6 IL2 CXCR3 CCR6 CCR5 CCR4
5 cell surface GO:0009986 9.61 TNF TGFBR3 IL2RA HLA-DRB1 HLA-B CXCR3
6 external side of plasma membrane GO:0009897 9.28 TNF TGFBR3 IL2RA HLA-DRB1 CXCR3 CD69

Biological processes related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.98 IL2RA IFNG CXCR3 CCR5
2 MAPK cascade GO:0000165 9.95 TNF IL2RA IL2 CCR5
3 positive regulation of protein phosphorylation GO:0001934 9.9 TNF IL2 IFNG HLA-DRB1
4 cellular response to lipopolysaccharide GO:0071222 9.89 TNF IL6 IL10 CCR5
5 chemotaxis GO:0006935 9.88 CXCR3 CCR6 CCR5 CCR4
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 TNF IL6 IL10
7 positive regulation of inflammatory response GO:0050729 9.84 TNF IL2 IFNG
8 interferon-gamma-mediated signaling pathway GO:0060333 9.81 IFNG HLA-DRB1 HLA-B
9 response to glucocorticoid GO:0051384 9.8 TNF IL6 IL10
10 positive regulation of T cell proliferation GO:0042102 9.8 IL6 IL2RA IL2
11 inflammatory response GO:0006954 9.8 TNF IL6 IL2RA CXCR3 CCR5 CCR4
12 cell chemotaxis GO:0060326 9.78 CXCR3 CCR6 CCR5 CCR4
13 negative regulation of T cell proliferation GO:0042130 9.76 IL2RA IL10 HLA-DRB1
14 calcium-mediated signaling GO:0019722 9.76 CXCR3 CCR6 CCR5 CCR4
15 positive regulation of cytokine secretion GO:0050715 9.71 TNF IL10 IFNG
16 chemokine-mediated signaling pathway GO:0070098 9.71 CXCR3 CCR6 CCR5 CCR4
17 positive regulation of JAK-STAT cascade GO:0046427 9.7 TNF IL6 IL10
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.69 TNF IFNG
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 TNF IL10
20 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.68 TNF IL6
21 positive regulation of chemokine biosynthetic process GO:0045080 9.68 TNF IFNG
22 positive regulation of neuroinflammatory response GO:0150078 9.68 TNF IL6
23 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL2
24 detection of bacterium GO:0016045 9.67 HLA-DRB1 HLA-B
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.67 TNF IL6 IL2 IFNG
26 interleukin-2-mediated signaling pathway GO:0038110 9.66 IL2RA IL2
27 negative regulation of amyloid-beta clearance GO:1900222 9.66 TNF IFNG
28 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IL10 IFNG
29 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
30 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.64 TNF IFNG
31 endothelial cell apoptotic process GO:0072577 9.64 TNF IL10
32 negative regulation of lymphocyte proliferation GO:0050672 9.62 IL2RA IL2
33 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
34 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 TNF IL10
35 regulation of regulatory T cell differentiation GO:0045589 9.61 IL2RA IL2 IFNG
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.57 TNF IFNG
37 regulation of T cell homeostatic proliferation GO:0046013 9.56 IL2RA IL2
38 humoral immune response GO:0006959 9.56 TNF IL6 IFNG CCR6
39 receptor biosynthetic process GO:0032800 9.55 TNF IL10
40 positive regulation of cytosolic calcium ion concentration GO:0007204 9.55 IL2 CXCR3 CCR6 CCR5 CCR4
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.51 TNF IFNG
42 positive regulation of nitrogen compound metabolic process GO:0051173 9.49 TNF IFNG
43 immune response GO:0006955 9.44 TNF TGFBR3 IL6 IL2RA IL2 IL10
44 cytokine-mediated signaling pathway GO:0019221 9.43 TNF IL6 IL2RA IL2 IL10 CCR5

Molecular functions related to Intermediate Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.24 TNF TGFBR3 MRAP IL6 IL2RA IL2
2 cytokine activity GO:0005125 9.72 TNF IL6 IL2 IL10 IFNG
3 chemokine binding GO:0019956 9.56 CXCR3 CCR6 CCR5 CCR4
4 C-C chemokine binding GO:0019957 9.46 CXCR3 CCR6 CCR5 CCR4
5 C-C chemokine receptor activity GO:0016493 9.26 CXCR3 CCR6 CCR5 CCR4
6 chemokine receptor activity GO:0004950 8.92 CXCR3 CCR6 CCR5 CCR4

Sources for Intermediate Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....